Clinical trials: Normal Upper Extremity, open to volunteers
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Breast Cancer Patients
Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation
Evaluation of the effectiveness and safety of laparoscopic assisted breast resection with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch for immediate one-step breast reconstruction…
- Trial name
- NCT07037537
- Testing
- Endoscopic assisted NSM+breast reconstruction+simultaneous fat transplantation
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Henan Cancer Hospital
Chronic Lower Leg Ulcer, Diabetic Lower Extremity Ulcers
Use of Hydroprep Wound Therapy With Motion Negative Pressure Therapy for Treatment of Chronic Lower Extremity Wounds
Use of a motorized waterjet to debride wounds to improve healing outcomes.
- Conditions
- Chronic Lower Leg Ulcer, Diabetic Lower Extremity Ulcers, Pressure Injuries, Traumatic Wounds and Injuries
- Trial name
- NCT07653165
- Testing
- Motion NPWT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- West Boca Center for Wound Healing
Arm Lymphedema, Breast Cancer
Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes
In this observational prospective studi patients with invasive breast cancer no more than 5 cm and clinically node negative, scheduled for conservative surgery and Sentinel Node Biopsy (SNB), are enrolled in the protocol if they…
- Conditions
- Arm Lymphedema, Breast Cancer, Radiotherapy Side Effect
- Trial name
- AXILL-ART (NCT06321653)
- Testing
- Hypofractionated radiotherapy scheme
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- European Institute of Oncology
Gastrointestinal Neoplasms
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who…
- Trial name
- NCT07689201
- Testing
- Velzatinib
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Sarcoma, Radiosurgery
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)
Up to 50% of soft tissue sarcoma (STS) patients will develop metastases in the course of their disease. Cytotoxic therapy is a standard treatment in this setting but yields average tumor response rates of 25% at first line and…
- Trial name
- Stereosarc (NCT03548428)
- Testing
- Atezolizumab, SBRT
- Where
- 17 sites in France
- Volunteers
- 103 people
- Sponsor
- Centre Antoine Lacassagne
Osteosarcoma, Osteosarcoma Metastatic
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
In advanced osteosarcoma where traditional chemotherapy has failed, the multi-targeted tyrosine kinase inhibitor apatinib has become a mainstream systemic treatment option in China.
- Trial name
- NCT07479732
- Testing
- Liposomal Irinotecan, Apatinib in arm1
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Peking University People's Hospital
Breast Carcinoma in Situ
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
This is a phase II single-center single-arm clinical study designed to analyze the efficacy and safety of trastuzumab combined with taxane neoadjuvant therapy for HER2-positive breast carcinoma in situ (or with invasive…
- Trial name
- NCT06843681
- Testing
- Trastuzumab combined with taxane neoadjuvant therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early Breast Cancer, HER2 + Breast Cancer
SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen.
- Conditions
- Early Breast Cancer, HER2 + Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT07129187
- Testing
- SHR-A1811
- Volunteers
- 30 people
- Sponsor
- Chuan Wang
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Glioblastoma (GBM)
Limited Target Volume Radiotherapy After Glioblastoma Surgery
Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity.
- Trial name
- NCT07368283
- Testing
- limited-field radiotherapy
- Volunteers
- 79 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Breast Cancer
SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
Studies have indicated that the improvement in pathological complete response (pCR) is significantly correlated with luminal breast cancer patients' overall survival (OS).
- Trial name
- NCT06402435
- Testing
- Lvonescimab (AK112)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hubei Cancer Hospital
Fracture Arm, Fracture Leg
Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms
The Accuro XV is a cart-based, bedside ultrasound instrument that incorporates new signal processing-based technologies for enhanced bone and soft-tissue imaging.
- Conditions
- Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury
- Trial name
- NCT07853768
- Testing
- Accuro XV Ultrasound Imaging System
- Where
- 10 sites in United States
- Volunteers
- 25,000 people
- Sponsor
- Rivanna Medical, Inc.
Triple-negative Breast Cancer, Bone Metastases
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
The goal of this clinical trial is to learn if Tislelizumab Combined with Nab-Paclitaxel works to treat patients of TNBC with bone metastasis as first line treatment. It will also learn about the safety of the combination.
- Trial name
- NCT06538896
- Testing
- Tislelizumab + Nab-Paclitaxel, Rankl inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Stage III
Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer
The purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by…
- Trial name
- RADAPT-N3 (NCT05896865)
- Testing
- Whole breast / chest wall & regional lymph node irradiation, Internal mammary or supraclavicular lymph node boost
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Samsung Medical Center
Breast Cancer, HER2-positive Breast Cancer
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP
This is a prospective, multi-center, single-arm, phase 2 exploratory study to evaluate the efficacy and safety of adding 4 cycles of Trastuzumab Rezetecan (T-DXh), an anti-HER2 antibody-drug conjugate, as continued neoadjuvant…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Trial name
- NCT07589699
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT06434064
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancers
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients
The goal of the study is to explore the efficacy and safety of hyperbaric oxygen therapy in the neoadjuvant treatment of triple-negative and HER2+ breast cancer patients
- Trial name
- NCT06825975
- Testing
- Hyperbaric oxygen treatment
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
This study evaluates HER2-PET/CT-guided dynamic optimization of neoadjuvant therapy in patients with early-stage HER2-positive breast cancer.
- Trial name
- NCT07527806
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab
- Volunteers
- 156 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
The primary objective of this study is to investigate the efficacy and safety of a fasting-mimicking diet (FMD) intervention combined with standard neoadjuvant chemoimmunotherapy in early-stage or locally advanced triple-negative…
- Trial name
- FACT-TN (NCT07378306)
- Testing
- Fasting-mimicking diet, Chemotherapy, Toripalimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University